Anteris Technologies Global Corp. — Capital/Financing Update 2021

Jun 2, 2021

ASX ANNOUNCEMENT

3 June 2021

ANTERIS RECEIVES $1.49M RESEARCH AND DEVELOPMENT TAX INCENTIVE REFUND

Anteris Technologies Ltd (ASX: AVR) ( Anteris or the Company ) is pleased to confirm the receipt of $1.49M under the Australian Government’s Research and Development (R&D) Tax Incentive Scheme. The claim covers the year ended 31 December 2020.

The Company will now repay the short-term facility entered into with Mitchell Asset Management Pty Ltd at the end of 2020 for the advance of $1.22M. This facility provided the Company with immediate funds equivalent to its forecasted R&D tax incentive offset for the majority of the 2020 calendar year. Information on this short-term facility was detailed in the ASX announcement dated 4 January 2021.

The Australian Government’s R&D Tax Incentive encourages companies to engage in R&D, by providing a refundable tax offset for eligible R&D activities, thereby assisting businesses to recover some of their costs related to R&D.

The R&D refund confirms Anteris’ significant and ongoing commitment to invest in, research and develop its ADAPT[®] technology and product development pipeline including DurAVR[TM] , Anteris’ 3D single-piece Aortic Valve.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT[®] tissue technology, paired with DurAVR™’s unique 3D singlepiece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

==> picture [95 x 51] intentionally omitted <==

Customer Service

Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson WE Communications E: WE-AUAnterisTech@we-worldwide.com P: +61 401 018 828 www.anteristech.com Twitter: @AnterisTech Facebook: www.facebook.com/AnterisTech

==> picture [95 x 52] intentionally omitted <==